Diabetes Therapy Podcast: Real-World Data for Glucose Sensing Technologies in Type 1 Diabetes Nick Oliver Commentary Open access 25 November 2022 Pages: 1 - 10
Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications Ali K. Abu-AlfaPaola J. AtallahThe Lebanese Consortium for Early, Comprehensive Management of Type 2 Diabetes (LCECMD) Guidelines Open access 15 December 2022 Pages: 11 - 28
Addendum 1: Forum for Injection Technique and Therapy Expert Recommendations, India Sanjay KalraAmbika G. UnnikrishnanGanapathi Bantwal Review Open access 15 November 2022 Pages: 29 - 45
Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis Hong WangXiaoya XieZhangui Tang Review Open access 09 December 2022 Pages: 47 - 61
Spatial Patterns and Determinants of Diabetes Mellitus in Indian Adult Population: a Secondary Data Analysis from Nationally Representative Surveys Yuvaraj KrishnamoorthySathish RajaaSanjay Kalra Original Research Open access 03 November 2022 Pages: 63 - 75
Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study Riccardo CandidoMonica Modugnothe ENSURE Study Group Original Research Open access 14 November 2022 Pages: 77 - 92
Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China Lei LiuZhen RuanLixin Guo Original Research Open access 22 November 2022 Pages: 93 - 107
Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study Sang-Yong KimSungrae Kim Original Research Open access 23 November 2022 Pages: 109 - 121
An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes Ildiko LingvayAndrei-Mircea CatarigLyndon Marc Evans Original Research Open access 25 November 2022 Pages: 123 - 137
Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Hypertensive and/or Diabetic People Aged over 60 Years: A Prospective Open-Label Study Rongdong HuangXiaoqin LiuDongjuan Zhang Original Research Open access 27 November 2022 Pages: 139 - 151
Sustained Improvement in Glycemic Control in Emerging Adults with Type 1 Diabetes 2 Years After the Start of the COVID-19 Pandemic Harshpreet SwaichAndrew Advani Original Research Open access 29 November 2022 Pages: 153 - 165
Risk Factors for Glycemic Control in Hospitalized Patients with Type 2 Diabetes Receiving Continuous Subcutaneous Insulin Infusion Therapy Shun-hua WangWei ShaoXue-jun Li Original Research Open access 01 December 2022 Pages: 167 - 178
Why Do So Many People with Type 2 Diabetes Who Take Insulin Have Lipohypertrophy? Fate or Educational Deficiencies? Sandro GentileGiuseppina GuarinoNefrocenter, Nyx Start-up, AMD-OSDI Study Group on Injection Techniques, ANIAD Original Research Open access 06 December 2022 Pages: 179 - 191
COVID-19 Vaccination and Diabetes Mellitus: How Much Has It Made a Difference to Outcomes Following Confirmed COVID-19 Infection? Adrian H. HealdDavid A. JenkinsWilliam Ollier Original Research Open access 07 December 2022 Pages: 193 - 204
Single-Field Fundus Photography for Screening of Diabetic Retinopathy: The Prevalence and Associated Factors in a Population-Based Study Mohammadreza SoleimaniFateme AlipourAmin Zand Original Research Open access 08 December 2022 Pages: 205 - 217
Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study Munehide MatsuhisaHideaki MiyoshiYasuo Terauchi Original Research Open access 23 November 2022 Pages: 219 - 236